Marta Zapata-Tarrés1, Juan Carlos Balandrán2,3, Roberto Rivera-Luna4, Rosana Pelayo5. 1. Fundación IMSS, A.C., Paseo de la Reforma 476, Mz Pte. Colonia Juárez, Alcaldía Cuauhtémoc, 06600, Mexico City, Mexico. 2. Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Department of Cell Biology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York, NY, 10461, USA. 3. Laboratorio Juárez, Medicina de Laboratorio Clínico de Alta Especialidad, Biología Molecular e Investigación Clínica, Sauces No. 512, Col. Reforma. Oaxaca de Juárez, Oaxaca, México. 4. National Institute of Pediatrics, Insurgentes Sur 3700-C, 04530, Mexico City, Mexico. riveraluna@yahoo.com. 5. Centro de Investigación Biomédica de Oriente CIBIOR, Instituto Mexicano del Seguro Social Delegación Puebla, Km. 4.5 Carretera Atlixco-Metepec, 74360, Puebla, Mexico. rosana.pelayo@imss.gob.mx.
Abstract
PURPOSE OF REVIEW: Acute leukemias represent a tremendous threat to public health around the globe and the main cause of death due to disease in scholar age children from developing nations. Here, we review their current status in Mexico, as a paradigm of study, and the major challenges to control systemic diseases like childhood cancer. RECENT FINDINGS: A unique molecular epidemiology, late/low precision diagnosis, limited access to treatment, toxicity associated with therapy, continuous exposure to environmental risk factors, and the high frequency of early relapses are some of the factors cooperating to low rates of survival in low-to-medium-income countries. Deliberative dialogues and exhaustive programs have emerged as promising means of advancing evidence-informed policy, by providing a structured forum for key stakeholders to integrate scientific and pragmatic knowledge about complex health concerns. A system-wide strategy based on the comprehensive leukemia identity is essential for a meaningful decline in early childhood mortality.
PURPOSE OF REVIEW: Acute leukemias represent a tremendous threat to public health around the globe and the main cause of death due to disease in scholar age children from developing nations. Here, we review their current status in Mexico, as a paradigm of study, and the major challenges to control systemic diseases like childhood cancer. RECENT FINDINGS: A unique molecular epidemiology, late/low precision diagnosis, limited access to treatment, toxicity associated with therapy, continuous exposure to environmental risk factors, and the high frequency of early relapses are some of the factors cooperating to low rates of survival in low-to-medium-income countries. Deliberative dialogues and exhaustive programs have emerged as promising means of advancing evidence-informed policy, by providing a structured forum for key stakeholders to integrate scientific and pragmatic knowledge about complex health concerns. A system-wide strategy based on the comprehensive leukemia identity is essential for a meaningful decline in early childhood mortality.
Authors: Nickhill Bhakta; Lisa M Force; Claudia Allemani; Rifat Atun; Freddie Bray; Michel P Coleman; Eva Steliarova-Foucher; A Lindsay Frazier; Leslie L Robison; Carlos Rodriguez-Galindo; Christina Fitzmaurice Journal: Lancet Oncol Date: 2019-01 Impact factor: 41.316
Authors: Juan Carlos Núñez-Enríquez; Diego Alberto Bárcenas-López; Alfredo Hidalgo-Miranda; Elva Jiménez-Hernández; Vilma Carolina Bekker-Méndez; Janet Flores-Lujano; Karina Anastacia Solis-Labastida; Gabriela Bibiana Martínez-Morales; Fausto Sánchez-Muñoz; Laura Eugenia Espinoza-Hernández; Martha Margarita Velázquez-Aviña; Laura Elizabeth Merino-Pasaye; Alejandra Jimena García Velázquez; María Luisa Pérez-Saldívar; Raúl Mojica-Espinoza; Julián Ramírez-Bello; Silvia Jiménez-Morales; Juan Manuel Mejía-Aranguré Journal: Arch Med Res Date: 2016-11 Impact factor: 2.235
Authors: Siobhan M Phillips; Lynne S Padgett; Wendy M Leisenring; Kayla K Stratton; Ken Bishop; Kevin R Krull; Catherine M Alfano; Todd M Gibson; Janet S de Moor; Danielle Blanch Hartigan; Gregory T Armstrong; Leslie L Robison; Julia H Rowland; Kevin C Oeffinger; Angela B Mariotto Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-04 Impact factor: 4.254
Authors: Claudia Allemani; Tomohiro Matsuda; Veronica Di Carlo; Rhea Harewood; Melissa Matz; Maja Nikšić; Audrey Bonaventure; Mikhail Valkov; Christopher J Johnson; Jacques Estève; Olufemi J Ogunbiyi; Gulnar Azevedo E Silva; Wan-Qing Chen; Sultan Eser; Gerda Engholm; Charles A Stiller; Alain Monnereau; Ryan R Woods; Otto Visser; Gek Hsiang Lim; Joanne Aitken; Hannah K Weir; Michel P Coleman Journal: Lancet Date: 2018-01-31 Impact factor: 79.321
Authors: Eva Steliarova-Foucher; Murielle Colombet; Lynn A G Ries; Florencia Moreno; Anastasia Dolya; Freddie Bray; Peter Hesseling; Hee Young Shin; Charles A Stiller Journal: Lancet Oncol Date: 2017-04-11 Impact factor: 41.316